Using advanced MRI to differentiate between cancerous and non-cancerous salivary gland tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to utilize advanced Magnetic Resonance Imaging (MRI) techniques to distinguish between benign and malignant salivary gland tumors. A total of 30 treatment-naïve patients with suspected salivary gland tumors will undergo a comprehensive MRI protocol that includes both anatomical imaging and dynamic contrast-enhanced imaging. The study will analyze specific imaging parameters to improve treatment strategies and predict disease progression based on the tumor's characteristics.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Possess a salivary gland lesion of 1cm3 size
* Have no prior history of treatment for salivary gland lesion

Exclusion Criteria:

* Has any prior history of cancer other than SGT
* Has any MRI contra-indications
* Has a history of known renal disease.
* Has history of prior radiation to head and neck region
* Is pregnant

Where it's running

• Hospital of the University of Pennsylvania
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: Sanjeev Chawla — Professor
• Study coordinator: Marisa Sanchez
• Email: Marisa.Sanchez@pennmedicine.upenn.edu
• Phone: 2159019994

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Analyzing immune biomarkers in salivary gland tumors

  This study is trying to see if analyzing the immune features of salivary gland tumors can help improve diagnosis and treatment for patients with these tumors.

  Recruiting at 2 sites University of Erlangen-Nürnberg Medical School · Erlangen, Bavaria and 1 other locations · NCT06047236

• Docetaxel and SX-682 in head and neck cancers and prostate cancer

  This trial tests a new drug SX-682 together with docetaxel in adults whose head and neck cancers or prostate cancer have returned or spread.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07667400

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Sacituzumab govitecan for advanced salivary gland and differentiated thyroid cancers

  This study will try sacituzumab govitecan in adults whose salivary gland cancer or radioactive-iodine–refractory differentiated thyroid cancer has spread or come back and cannot be removed by surgery.

  Recruiting Phase 2 National University Hospital, Singapore · Singapore · NCT06923826

• Evaluating Ivonescimab for advanced salivary gland cancers

  This study is testing a new treatment called Ivonescimab to see if it can help people with advanced salivary gland cancers feel better and improve their health.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06805617

• Evaluating zanidatamab for HER2-expressing tumors

  This study is testing a new drug called zanidatamab to see if it can help people with certain types of cancer that have high levels of HER2 and who have already tried other treatments without success.

  Recruiting at 30 sites Phase 2 Jazz Pharmaceuticals · Prescott, Arizona and 41 other locations · NCT06695845

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.